WHO WE ARE
Started in 2003, BioSafe is the Biotechnology Innovation Organization’s preclinical safety committee within BIO’s health section, comprised of >300 BIO members working to identify key scientific and regulatory issues and developments related to the preclinical safety evaluation of biopharmaceutical products and recommending appropriate science-based responses.
The mission of BioSafe is to play a key role in driving the innovation of biopharmaceuticals by identifying and addressing key regulatory and translational science issues related to preclinical safety and PKPD, expediting time to market and serving the needs of BIO.
There is a close connection with BIO’s Cell and Gene Therapy Non-Clinical Task Force which give regular updates and opportunities for collaboration at our meetings.